Twenty-four male Wistar rats were randomized into four groups. All of the experimental rats were fed and housed at Eulji Medical University, following the above-mentioned guidelines. The rats were divided into the following groups: Saline + Sham group (n = 6), intraperitoneal (ip) injection of saline 24 h prior to sham laparotomy; Paricalcitol + Sham group (n = 6), an equivalent volume of Paricalcitol (Zemplar; Abbott Laboratories, Abbott Park, IL, USA) (20 μg/kg ip) injection 24 h prior to sham laparotomy; Saline + I/R group (n = 6), pretreatment with saline (ip) injection 24 h prior to hepatic I/R; and Paricalcitol + I/R group (n = 6), pretreatment with Paricalcitol (20 μg/kg ip) injection 24 h prior to hepatic I/R. The proper dosage and injection time of Paricalcitol prior to surgery were determined by a series of preliminary examinations (data not shown).
Paricalcitol
Manufactured by Abbott
Sourced in United States
Paricalcitol is a synthetic vitamin D analogue developed by Abbott Laboratories for use in the treatment of secondary hyperparathyroidism associated with chronic kidney disease. It functions by selectively activating the vitamin D receptor, leading to the regulation of calcium and phosphorus metabolism.
Automatically generated - may contain errors
Lab products found in correlation
Zemplar, by Abbott (2 mentions)
Dulbecco s modified eagle s medium f12 medium, by Merck Group (1 mentions)
Ly294, by Merck Group (1 mentions)
Penicillin, by Merck Group (1 mentions)
Streptomycin, by Merck Group (1 mentions)
N acetyl l cysteine, by Merck Group (1 mentions)
Hk 2 human proximal tubular epithelial cells, by Thermo Fisher Scientific (1 mentions)
Tweak, by Merck Group (1 mentions)
Ab 100 na, by R&D Systems (1 mentions)
Rpmi 1640, by Thermo Fisher Scientific (1 mentions)
Tgf β1, by Thermo Fisher Scientific (1 mentions)
Indomethacin, by Fujifilm (1 mentions)
Indomethacin, by Abbott (1 mentions)
8 protocols using paricalcitol
1
Paricalcitol Pretreatment and Hepatic I/R Injury
2
Cultivating HK-2 Cells for Experimental Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Human renal proximal tubular epithelial cells (HK-2, ATCC, Manassas, VA, USA) were cultured and passaged every 3 to 4 days in 100-mm dishes containing Dulbecco’s modified Eagle’s medium-F-12 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma-Aldrich). Cells were incubated in a humidified atmosphere of 5% CO2 and 95% air at 37°C for 24 hours and sub-cultured at 70% to 80% confluence. For experiments, HK-2 cells were plated onto 60-mm dishes in medium containing 10% fetal bovine serum for 24 hours, and cells were then switched to Dulbecco’s modified Eagle’s medium F12 serum-free media for 24 hours. Cells were harvested at the end of treatment for further analysis. IS was obtained from Sigma-Aldrich (Steinheim, Germany), and paricalcitol was obtained from Abbott Laboratories (North Chicago, IL, USA). PD98059 (a mitogen-activated protein kinase [MAPK]/extracellular signal-related kinase [Erk] inhibitor), SP600125 (a specific Jnk inhibitor), and SB203580 (a p38 MAPK inhibitor) were obtained from Calbiochem (San Diego, CA, USA). Ly294 (a phosphoinositide 3-kinase/protein kinase B [Akt] inhibitor) and N-acetyl-L-cysteine were obtained from Sigma-Aldrich (Steinheim). Bay 11-7082 was obtained from Biomol (Plymouth Meeting, PA, USA).
3
Proximal Tubular Epithelial Cell Culture
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
HK‐2 human proximal tubular epithelial cells (ATCC, Rockville, MD, USA) were grown on RPMI 1640 (Life Technologies, Grand Island, NY, USA) with 10% heat‐inactivated FBS, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml sodium selenite and 5 ng/ml hydrocortisone in 5% carbon dioxide at 37°C 17 . VHL‐defective clear cell renal carcinoma cells (VHL−/− ccRCC) and VHL+/+ ccRCC cells have been previously described 18 . For experiments, cells were rested in serum‐free media 24 hr prior to the addition of stimuli and throughout the experiment. Five hundred thousand cells were seeded in 60 mm diameter wells for RNA extraction, Western blot or flow cytometry experiments. Cells were treated with 100 ng/ml TWEAK (Millipore, Watford, UK), 1 ng/ml TGFβ1 (Peprotech, London, UK), 100 nmol/l paricalcitol (Abbot, Chicago, Illinois), 100 μmol/l TGFβ1 receptor 1 (ALK5) inhibitor (SB431542; Sigma‐Aldrich, Sigma, St. Louis, MO) or 1 ng/ml neutralizing anti‐TGFβ1 antibody (ab100NA; R&D Systems, Minneapolis, MN), based on prior dose–responses studies from our lab.
4
Neuroprotective Effects of Paricalcitol in Ischemic Stroke
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The surviving rats were randomly assigned to one of two treatment groups: the paricalcitol group (n = 8), which was injected intraperitoneally with paricalcitol (Zemplar; Abbott Laboratories, Abbott Park, IL) (1 μg/kg), and the normal saline group (n = 8), which was injected intraperitoneally with an equivalent volume of normal saline. A previous study showed that a low dose of calcitriol (1 μg/kg) reduced HIBI in a rat model of transient middle cerebral artery occlusion [12 (link)]. Therefore, we chose to use the low dose of 1 μg/kg to avoid potential side effects such as hypercalcemia and hyperphosphatemia. After recovery of the righting reflex, rats were returned to their cages and observed until 4 days after cerebral ischemia. During the observational period, we injected paricalcitol (1 μg/kg) intraperitoneally, or an equivalent volume of normal saline in the control group, on days 1, 2, and 3 post-ischemia.
5
Sepsis Induction and Vitamin D Analog Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All mice were from a C57BL/6 background. This study was carried out in accordance with the recommendations of the guidelines of the Animal Care Committee of Nanjing Medical University. The protocol was approved by the Animal Care Committee of Nanjing Medical University. Mice were used experimentally at 2–4 months of age. To induce sepsis, we injected mice with one dose of LPS (O111:B4, Sigma L2630; 10 mg/kg i.p.). We treated mice with vehicle (60:30:10 propylene glycol:water:ethanol) or the non-calcemic vitamin D analog paricalcitol (19-nor-1,25-dihydroxyvitamin D2, 200 ng/kg; provided by Abbott Laboratories) after an LPS (20 mg/kg) challenge. Blood was collected for serum cytokine measurement from the tail vein at the indicated times after LPS treatment.
6
Paricalcitol Neuroprotection in Cerebral Ischemia
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Surviving rats were randomly assigned to one of the two treatment groups: paricalcitol group (n = 8), injected intraperitoneally with paricalcitol (Zemplar; Abbott Laboratories, Abbott Park, IL) (1 μg/kg); and normal saline group (n = 8), injected intraperitoneally with an equivalent volume of normal saline. We administered drugs 5 min after the end of the ischemic period. After recovery of righting re ex, rats were returned to the cages and observed until four days after cerebral ischemia. During the observational period, we intraperitoneally injected paricalcitol (1 μg/kg) or an equivalent volume of normal saline on days 1, 2 and 3 post-ischemia.
7
Vitamin D3 and Paricalcitol Impacts on EAE
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice were treated with 8 or 4 doses of 0.1 ug/day of vitamin D3 (D1530- Millipore-Sigma) or paricalcitol (Zemplar®, Abbott Laboratories, Chicago, IL, EUA) by ip route every other day, starting 7 days after EAE induction. The CTL and EAE group were injected with the vehicle in the same frequency.
8
Contrast-Induced Acute Kidney Injury in Rats
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Twenty-eight rats were divided into four groups: control (Con, n = 7), Paricalcitol alone (PC, n = 7), contrast alone (CONT, n = 7), and Paricalcitol prior to contrast infusion (PC+CONT, n = 7). We used a previously published protocol to produce CI-AKI [21 (link)]. Rats were initially given indomethacin (10 mg/kg; Wako Pure Chemical Corporation, Osaka, Japan), which was followed by N-ω nitro-L-arginine methyl ester (10 mg/kg; Wako Pure Chemical Corporation) and ioversol (8.3 mL/kg of organically bound iodine) via intravenous injection into the tail vein 15 and 30 min later, respectively. Paricalcitol 0.3 μg/kg (Abbott Co., Seoul, Korea) was given intraperitoneally 24 h and 30 min before indomethacin (Supplementary Fig. 1 ). Controls received phosphate-buffered saline (PBS). Rats were sacrificed 6, 12, 24, and 48 h after ioversol injection, and blood and kidney tissues were harvested.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!